Global Perspectives in Breast Cancer
Expert perspectives and strategic insights on the latest therapeutic developments in breast cancer
Faculty Chair
Joyce O’Shaughnessy, MD
Texas Oncology, Dallas, TX, USA
Faculty Members
Hope Rugo, MD, FASCO
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA
Mark Pegram, MD
Stanford Women’s Cancer Center, Palo Alto, CA, USA
William Gradishar, MD
Northwestern University Feinberg School of Medicine, Chicago, IL, USA
Jame Abraham, MD, FACP
Cleveland Clinic, Cleveland, OH, USA
Adam Brufsky, MD, PhD, FACP
University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
Komal L. Jhaveri, MD
Memorial Sloan Kettering Cancer Center, New York, NY, USA
Peter Kaufman, MD
University of Vermont, Burlington, VT, USA
William Sikov, MD
Women & Infants Hospital of Rhode Island, Providence, RI, USA
Harold Burstein, MD, PhD
Dana-Farber Cancer Institute, Boston, MA, USA
KEY TAKEAWAYS AND STRATEGIC INSIGHTS
The meeting report will be based on the following topics
- Evolving Paradigms in HER2+ MBC
- Individualizing Therapy for HER2+ Early Breast Cancer
- Current and Investigational Approaches in Metastatic Triple-Negative Breast Cancer
- Standard and Emerging Strategies for High-Risk Early Stage Triple-Negative Breast Cancer
- Novel Targets in Breast Cancer
- Evolving Treatments and New Developments in HR+ Metastatic Breast Cancer
- Evolving Paradigms in HR+ Early Breast Cancer
